Guaranteed rights in China for anti-ROR1 monoclonal antibodies and their uses until 2039
Chinese anti-cancer market evaluated as attractive due to high market performance and improved approval system
(Photo = ABL Bio)
[바이오타임즈] ABL Bio (CEO Lee Sang-hoon), a company specializing in bispecific antibodies, announced on the 5th that it has completed registration of a Chinese patent for an anti-ROR1 antibody that inhibits ROR1, which is overexpressed in various carcinomas such as solid cancer and blood cancer, and its use.
The patent right is guaranteed until 2039, and examinations for patent registration are underway in many countries, including the United States and Europe, in addition to Korea, Japan, and China, which were previously granted.
ROR1 is a target that attracts attention as it can target various cancer types by being overexpressed in various cancer types from solid cancer to hematological cancer. ABL Bio also developed the ROR1 ADC pipeline ABL202 (CS5001, LCB71) through collaboration with LegoChem Bio. there is. ABL202 is competitive by combining ABL Bio’s excellent ROR1 antibody with LegoChem Bio’s blood stable linker and Pro PBD in an optimal ratio, and this is being confirmed as clinical trials progress.
ABL202 has transferred technology to CStone Pharmaceuticals, a listed company in Hong Kong, and is undergoing phase 1 clinical trials. there is.
At the World ADC London held in London in March of this year, it was confirmed through the non-clinical data presented by C-Stone that it exhibits superior tumor suppression efficacy compared to competitors’ ADC benchmarks at a lower dose. It is hoped that additional data will be made public.
Lee Sang-hoon, CEO of ABL Bio, said, “China has more than twice as many cancer patients as the US, which is the No. 1 anti-cancer market, and nearly five times as many patients die from cancer. As a result, 31 out of 49 new drugs approved in 2020 were approved through the expedited approval system, and China is an attractive market with high marketability and a system to support it.” , I think the Chinese patent registration, which was preemptively carried out, is also meaningful.”
Meanwhile, ABL001 (VEGFxDLL4), ABL111 (Claudin18.2×4-1BB), ABL503 (PD-L1x4-1BB), ABL105 (HER2x4-1BB), ABL202 (ROR1 ADC), ABL301 (a-synxIGF1R) developed by ABL Bio , ABL103 (B7-H4x4-1BB), and more than 14 global clinical trials in the US, China, Australia and Korea for more than 7 pipelines are in progress, and pipelines such as ABL104 (EGFRx4-1BB) are also preparing for clinical entry. in progress In addition, research and development of a number of non-clinical pipelines, including ABL102 (ROR1x4-1BB) and ABL602 (CLL1xCD3), are also actively underway.
[바이오타임즈=김수진 기자] sjkimcap@biotimes.co.kr
Copyright © Biotimes Unauthorized reproduction and redistribution prohibited
2023-09-05 02:40:21
#ABL #Bio #completed #Chinese #patent #registration #ROR1 #antibody
